基于网络药理学和分子对接探讨黄连温胆汤治疗幽门螺杆菌相关性胃炎的作用机制

doi:10.3976/j.issn.1002-4026.2023.02.004

Abstract

Abstract:

This study aimed to explore the mechanism of Huanglian Wendan Decoction in the treatment of Helicobacter pylori associated gastritis by network pharmacology and molecular docking methods. The active ingredients and drug target genes of Huanglian Wendan Decoction were screened using the traditional Chinese medicine system pharmacology database and analysis platform. The H. pylori associated gastritis disease-related targets were found by the GeneCards and DisGENET databases, and the common target genes of diseases and drugs were obtained via the Venny online mapping tool. Cytoscape 3.8.2 software and the STRING database were used to construct a drug-compound-target interaction network and a protein-protein interaction network diagram, respectively. Gene ontology function and Kyoto encyclopedia of genes and genomes pathway enrichment analysis were performed using the DAVID database. The target proteins and active ingredients with the top three selection scores were selected for molecular docking using Autodocktools 1.5.6 software. A total of 127 active ingredients of Huanglian Wendan Decoction were screened, such as quercetin, nobiletin, and naringenin. A total of 101 potential target proteins were obtained, such as Akt1, JUN, TNF-α, and STAT3, which involved 90 signal pathways, including the p53 signal pathway, NOD-like receptor signal pathway, and TNF signal pathway. Molecular docking results revealed that the key targets, STAT3, TP53, and Akt1, had high affinity for the active ingredients quercetin, nobiletin, and naringenin. In addition, Akt1 had the highest binding affinity for naringenin. Network pharmacology and molecular docking analysis predicted the action target and related signal pathway of Huanglian Wendan Decoction in the treatment of H. pylori associated gastritis, which will provide a theoretical basis for clinical application and subsequent experimental research.

Key words: Huanglian Wendan Decoction, Helicobacter pylori associated gastritis, network pharmacology, molecular docking

CLC Number:

R285

LIU Wenwen, GAO Yunyun, YIN Zhipeng, LÜ Gang, WANG Yu, ZHAO Yinghui. Network pharmacology and molecular docking analysis of the mechanism of Huanglian Wendan Decoction in the treatment of Helicobacter pylori associated gastritis[J].Shandong Science, 2023, 36(2): 23-32.

Figures/Tables 5

Table 1

Table 2

Table 3

Table 4

Fig.1

References 46

[1]	PELLICANO R, RIBALDONE D G, FAGOONEE S, et al. A 2016 panorama of Helicobacter pylori infection: Key messages for clinicians[J]. Panminerva Medica, 2016, 58(4): 304-317.
[2]	ROSZCZENKO-JASINSKA P, WOJTYS M I, JAGUSZTYN-KRYNICKA E K. Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets[J]. Applied Microbiology and Biotechnology, 2020, 104(23): 9891-9905. DOI:10.1007/s00253-020-10945-w. doi: 10.1007/s00253-020-10945-w
[3]	SUGANO K, HIROI S, YAMAOKA Y. Prevalence of Helicobacter pylori infection in Asia: Remembrance of things past?[J]. Gastroenterology, 2018, 154(1): 257-258. DOI:10.1053/j.gastro.2017.08.074. doi: 10.1053/j.gastro.2017.08.074
[4]	XU X L, LI W D, QIN L, et al. Relationship between Helicobacter pylori infection and obesity in Chinese adults: A systematic review with meta-analysis[J]. PLoS One, 2019, 14(9): e0221076. DOI:10.1371/journal.pone.0221076. doi: 10.1371/journal.pone.0221076
[5]	CHEN Q, LU H. Kyoto global consensus report on Helicobacter pylori gastritis and its impact on Chinese clinical practice[J]. Journal of Digestive Diseases, 2016, 17(6): 353-356. DOI:10.1111/1751-2980.12358. doi: 10.1111/1751-2980.12358
[6]	MALFERTHEINER P, MEGRAUD F, O'MORAINC A, et al. Management of Helicobacter pylori infection-the maastricht V/Florence consensus report[J]. Gut, 2017, 66(1): 6-30. DOI:10.1136/gutjnl-2016-312288. doi: 10.1136/gutjnl-2016-312288
[7]	刘文忠. “第五次全国幽门螺杆菌感染处理共识报告”解读[J]. 胃肠病学, 2017, 22(6): 321-324.
[8]	WHO. Who publishes list of bacteria for which new antibiotics are urgently needed[J]. Neurosciences, 2017, 22(2): 159-160.
[9]	郑莉. 中医药治疗幽门螺杆菌相关性胃炎研究现状[J]. 内蒙古中医药, 2020, 39(4): 167-168. DOI:10.16040/j.cnki.cn15-1101.2020.04.098. doi: 10.16040/j.cnki.cn15-1101.2020.04.098
[10]	范志欣, 杨晓军, 黄敏玲, 等. 基于网络药理学探讨黄连温胆汤“心胃同治”作用机制[J]. 现代中西医结合杂志, 2020, 29(25): 2788-2792. DOI:10.3969/j.issn.1008-8849.2020.25.012. doi: 10.3969/j.issn.1008-8849.2020.25.012
[11]	张磊. 黄连温胆汤治疗脾胃湿热型幽门螺杆菌阳性浅表性胃炎的疗效观察[J]. 内蒙古中医药, 2020, 39(10): 8-10. DOI:10.16040/j.cnki.cn15-1101.2020.10.004. doi: 10.16040/j.cnki.cn15-1101.2020.10.004
[12]	RU JL, LI P, WANG J N, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines[J]. Journal of Cheminformatics, 2014, 6: 13. DOI:10.1186/1758-2946-6-13. doi: 10.1186/1758-2946-6-13 pmid: 24735618
[13]	张彧, 吴东升, 徐寅, 等. 基于网络药理学分析半夏-黄芩-黄连治疗幽门螺杆菌相关性胃炎的作用机制[J]. 天然产物研究与开发, 2020, 32(4): 592-599. DOI:10.16333/j.1001-6880.2020.4.007. doi: 10.16333/j.1001-6880.2020.4.007
[14]	PIÑERO J, RAMÍREZ-ANGUITA J M, SAÜCH-PITARCH J, et al. The DisGeNET knowledge platform for disease genomics: 2019 update[J]. Nucleic Acids Research, 2019, 48(D1): D845-D855. DOI:10.1093/nar/gkz1021. doi: 10.1093/nar/gkz1021
[15]	KIM S Y, SPEED T P. Comparing somatic mutation-callers: Beyond Venn diagrams[J]. BMC Bioinformatics, 2013, 14: 189. DOI:10.1186/1471-2105-14-189. doi: 10.1186/1471-2105-14-189 pmid: 23758877
[16]	SHANNON P, MARKIEL A, OZIER O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks[J]. Genome Research, 2003, 13(11): 2498-2504. DOI:10.1101/gr.1239303. doi: 10.1101/gr.1239303 pmid: 14597658
[17]	SZKLARCZYK D, GABLE A L, NASTOU K C, et al. The STRING database in 2021: Customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets[J]. Nucleic Acids Research, 2020, 49(D1): D605-D612. DOI:10.1093/nar/gkaa1074. doi: 10.1093/nar/gkaa1074
[18]	韩利文, 陈善军, 董榕, 等. 网络药理学在中药复杂作用模式研究中的应用进展[J]. 山东科学, 2021, 34(6): 22-31. doi: 10.3976/j.issn.1002-4026.2021.06.004
[19]	KIM S. Exploringchemical information in PubChem[J]. Current Protocols, 2021, 1(8): e217. DOI:10.1002/cpz1.217. doi: 10.1002/cpz1.217
[20]	黄浩然, 陈蔚文, 徐晖. 中药及其有效成分抑制幽门螺杆菌的研究进展[J]. 中药新药与临床药理, 2008, 19(6): 508-511. DOI:10.19378/j.issn.1003-9783.2008.06.034. doi: 10.19378/j.issn.1003-9783.2008.06.034
[21]	SATO S, MUKAI Y. Modulation ofchronic inflammation by quercetin: The beneficial effects on obesity[J]. Journal of Inflammation Research, 2020, 13: 421-431. DOI:10.2147/JIR.S228361. doi: 10.2147/JIR.S228361
[22]	ZHANG S, HUANG J, XIE X Q, et al. Quercetin from Polygonum capitatum protects against gastric inflammation and apoptosis associated with Helicobacter pylori infection by affecting the levels of p38MAPK, BCL-2 and BAX[J]. Molecules (Basel, Switzerland), 2017, 22(5): 744. DOI:10.3390/molecules22050744. doi: 10.3390/molecules22050744
[23]	杨小红, 陆锦, 骆询, 等. 黄芩、黄连和大黄对幽门螺杆菌抑菌作用的研究进展[J]. 中国药房, 2015, 26(14): 2014-2016.
[24]	HADDADI N, LIN Y G, TRAVIS G, et al. PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy[J]. Molecular Cancer, 2018, 17(1): 37. DOI:10.1186/s12943-018-0803-3. doi: 10.1186/s12943-018-0803-3
[25]	COSTA R L B, HAN H S, GRADISHAR W J. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: A review[J]. Breast Cancer Research and Treatment, 2018, 169(3): 397-406. DOI:10.1007/s10549-018-4697-y. doi: 10.1007/s10549-018-4697-y pmid: 29417298
[26]	XIE C, YI J, LU J, et al. N-acetylcysteine reduces ROS-mediated oxidative DNA damage and PI3K/Akt pathway activation induced by Helicobacter pylori infection[J]. Oxidative Medicine and Cellular Longevity, 2018, 2018: 1874985. DOI:10.1155/2018/1874985. doi: 10.1155/2018/1874985
[27]	TOLLERI M, NEELSEN K J, STEGER M, et al. Carcinogenic bacterial pathogen Helicobacter pylori triggers DNA double-strand breaks and a DNA damage response in its host cells[J]. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108(36): 14944-14949. DOI:10.1073/pnas.1100959108. doi: 10.1073/pnas.1100959108
[28]	TAOZ H, FANG J Y. The complicated dialogue between Helicobacter pylori and p53[J]. Gut, 2020, 69(11): 2052-2053. DOI:10.1136/gutjnl-2020-320630. doi: 10.1136/gutjnl-2020-320630
[29]	BARTCHEWSKY W, MARTINIM R, SQUASSONI A C, et al. Effects of Helicobacter pylori infection on the expressions of bax and bcl-2 in patients with chronic gastritis and gastric cancer[J]. Digestive Diseases and Sciences, 2009, 55(1): 111-116. DOI:10.1007/s10620-008-0699-7. doi: 10.1007/s10620-008-0699-7
[30]	赵瑞珍. 黄连温胆汤对大鼠慢性胃炎的病理及bcl-2、bax蛋白表达影响的实验研究[D]. 成都: 成都中医药大学, 2012.
[31]	李杰, 熊礼杭, 严洁. 幽门螺杆菌Tip α蛋白经激活NF-kB对巨噬细胞分泌细胞因子诱导机制分析[J]. 智慧健康, 2020, 6(9): 7-8. DOI:10.19335/j.cnki.2096-1219.2020.9.004. doi: 10.19335/j.cnki.2096-1219.2020.9.004
[32]	郑轶, 刘颜敏, 陈志涛, 等. 幽门螺杆菌感染的胃癌和癌前病变组织中肿瘤坏死因子-α的表达及临床意义[J]. 临床内科杂志, 2020, 37(10): 718-720. DOI:10.3969/j.issn.1001-9057.2020.10.013. doi: 10.3969/j.issn.1001-9057.2020.10.013
[33]	CHEN G D, TANG N, WANG C, et al. TNF-α-inducing protein of Helicobacter pylori induces epithelial-mesenchymal transition (EMT) in gastric cancer cells through activation of IL-6/STAT3 signaling pathway[J]. Biochemical and Biophysical Research Communications, 2017, 484(2): 311-317. DOI:10.1016/j.bbrc.2017.01.110. doi: 10.1016/j.bbrc.2017.01.110
[34]	杨鑫. 肥胖对幽门螺杆菌感染后胃黏膜炎症与STAT3表达的影响[D]. 青岛: 青岛大学, 2020.
[35]	PIAO J Y, LEE H G, KIM S J, et al. Helicobacter pylori activates IL-6-STAT3 signaling in human gastric cancer cells: Potential roles for reactive oxygen species[J]. Helicobacter, 2016, 21(5): 405-416. DOI:10.1111/hel.12298. doi: 10.1111/hel.12298
[36]	KACAR F, METEOğLU I, YASA H D, et al. Helicobacter pylori-induced changes in the gastric mucosa are associated with mitogen-activated protein kinase (MAPK) activation[J]. Applied Immunohistochemistry & Molecular Morphology: AIMM, 2007, 15(2): 224-228. DOI:10.1097/01.pai.0000209863.35828.dd. doi: 10.1097/01.pai.0000209863.35828.dd
[37]	GUOY J, PAN W W, LIU S B, et al. ERK/MAPK signalling pathway and tumorigenesis[J]. Experimental and Therapeutic Medicine, 2020, 19(3): 1997-2007. DOI:10.3892/etm.2020.8454. doi: 10.3892/etm.2020.8454
[38]	KYRIAKISJ M, AVRUCH J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation[J]. Physiological Reviews, 2001, 81(2): 807-869. DOI:10.1152/physrev.2001.81.2.807. doi: 10.1152/physrev.2001.81.2.807 pmid: 11274345
[39]	SLOMIANYB L, SLOMIANY A. Helicobacter pylori -induced gastric mucosal TGF-α ectodomain shedding and EGFR transactivation involves Rac1/p38 MAPK-dependent TACE activation[J]. Inflammopharmacology, 2016, 24(1): 23-31. DOI:10.1007/s10787-015-0254-z. doi: 10.1007/s10787-015-0254-z pmid: 26658844
[40]	MA X Q, YOU P T, XU Y, et al. Anti-Helicobacter pylori-associated gastritis effect of the ethyl acetate extract of Alpinia officinarum Hance through MAPK signaling pathway[J]. Journal of Ethnopharmacology, 2020, 260: 113100. DOI:10.1016/j.jep.2020.113100. doi: 10.1016/j.jep.2020.113100
[41]	陶飞宝, 何钦, 叶旭星, 等. 黄连温胆汤加味治疗Hp相关性胃炎的疗效及对细胞因子的影响[J]. 内蒙古中医药, 2019, 38(8): 1-3. DOI:10.16040/j.cnki.cn15-1101.2019.08.001. doi: 10.16040/j.cnki.cn15-1101.2019.08.001
[42]	杜江, 欧希龙, 俞文秀. TLR4及MYD88多态性与江苏地区幽门螺杆菌感染的相关性研究[J]. 现代消化及介入诊疗, 2018, 23(4): 433-437. DOI:10.3969/j.issn.1672-2159.2018.04.001. doi: 10.3969/j.issn.1672-2159.2018.04.001
[43]	秦凯凯. Toll样受体2、4、5在幽门螺杆菌相关胃炎及胃溃疡中的表达及意义[D]. 大连: 大连医科大学, 2016.
[44]	MELIŢ L E, MĂRGINEAN C O, MĂRGINEAN C D, et al. The relationship between toll-like receptors and Helicobacter pylori-related gastropathies: Still a controversial topic[J]. Journal of Immunology Research, 2019, 2019: 8197048. DOI:10.1155/2019/8197048. doi: 10.1155/2019/8197048
[45]	辛洪杰, 白杨. NOD样受体在幽门螺杆菌感染和胃癌中的研究进展[J]. 现代消化及介入诊疗, 2020, 25(2): 256-261.
[46]	CASTAÑO-RODRÍGUEZ N, KAAKOUSH N O, GOH K L, et al. The NOD-like receptor signalling pathway in Helicobacter pylori infection and related gastric cancer: A case-control study and gene expression analyses[J]. PLoS One, 2015, 10(1): e0117870. DOI:10.1371/journal.pone.0117870. doi: 10.1371/journal.pone.0117870

药物	MOL ID	共同活性成分	OB/%	DL
黄连-甘草	MOL000098	槲皮苷(quercetin)	46.43	0.28
半夏-生姜	MOL000449	豆甾醇(stigmasterol)	43.83	0.76
半夏-生姜	MOL000358	β-谷甾醇 (beta-sitosterol)	36.91	0.75
陈皮-枳实	MOL005828	川皮苷(nobiletin)	61.67	0.52
陈皮-枳实	MOL005100	5,7-二羟基-2-(3-羟基-4-甲氧基苯基)-色满-4-酮	47.74	0.27
陈皮-枳实-甘草	MOL004328	柚皮素(naringenin)	59.29	0.21
陈皮-甘草	MOL000359	谷甾醇(sitosterol)	36.91	0.75

药物	活性成分	MOL ID	度值
黄连-甘草	槲皮素(quercetin)	MOL000098	133
陈皮-枳实	川皮苷(nobiletin)	MOL005828	39
陈皮-枳实-甘草	柚皮素(naringenin)	MOL004328	37
甘草	毛蕊异黄酮(calycosin)	MOL000417	31
半夏-生姜	β-谷甾醇(beta-sitosterol)	MOL000358	27
半夏	黄芩素(baicalein)	MOL002714	18
甘草	槲皮素衍生物(quercetin der)	MOL004961	16
枳实	四甲氧基乌托林(tetramethoxyluteolin)	MOL007879	38

蛋白名称	基因名称	度值
前列腺素G/H合酶2	PTGS2	121
热休克蛋白90α	HSP90AA1	86
雄激素受体	AR	84
诱导型一氧化氮合酶	NOS2	78
过氧化物酶体增殖物激活受体	PPARG	75
前列腺素G/H合酶1	PTGS1	71
糖原合成酶激酶3β	GSK3B	58
丝氨酸-苏氨酸蛋白激酶Chk1	CHEK1	51
丝裂原活化蛋白激酶14	MAPK14	47
凝血酶原	F2	43
内皮型一氧化氮合酶	NOS3	23
毒蕈碱乙酰胆碱受体M3	CHRM3	16
孕酮受体	PGR	13
凋亡调节因子Bcl-2	BCL2	12
溶质载体家族6	SLC6A4	11

编号	化合物名称	结合自由能/(kJ·mol^-1)			DS(LibDock Score)
编号	化合物名称	STAT3	TP53	Akt1	STAT3	TP53	Akt1
MOL000098	槲皮素	-6	-6.4	-9.2	99.71	93.06	110.1
MOL005828	川皮苷	-5.4	-5.8	-6.3	57.39	74.86	84.86
MOL004328	柚皮素	-6.1	-6.6	-8.9	102.8	105.5	111.9

Network pharmacology and molecular docking analysis of the mechanism of Huanglian Wendan Decoction in the treatment of Helicobacter pylori associated gastritis

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 46

Related Articles 15

Metrics

Comments

Recommended 0

[1]	SUN Jingtian, LIU Feng, ZHANG Zhe, ZHANG Yufu, MA Xinhui, LI Qingjun, WANG Xiao, DONG Hongjing. Exploring the medication rule of Chrysanthemum morifolium Ramat. and investigating the synergistic pharmacological activity of core combination herbs [J]. Shandong Science, 2025, 38(1): 1-8.
[2]	HAN Huijie, LIU Hui, ZHAO Yongbo, WANG Songpo. A study based on network pharmacology and experimental verification exploring the mechanism of quercetin against colorectal cancer through the p53 signaling pathway [J]. Shandong Science, 2025, 38(1): 32-43.
[3]	FAN Wei, SHEN Chuanlin, ZHANG Xuanming, DU Xingshuo, ZHAN Wen, SUN Chen, JIN Meng, LI Xiaobin, ZHANG Sichen, SUN Botong, HE Qiuxia. Prediction of anti-aging mechanism of Panax quinquefolius L. by network pharmacology and molecular docking [J]. Shandong Science, 2024, 37(6): 42-50.
[4]	YAN Jin, LI Fei, WU Keming, YANG Haobo. The molecular mechanisms by which Xinjia Cistanche Tusi Decoction promotes follicular development through mitophagy [J]. Shandong Science, 2024, 37(5): 25-34.
[5]	LIN Shenghua, XUE Chang, MA honglin, FAN Wei, SHEN Chuanlin, CHEN Jiayu, SUN Botong, DU Xingshuo, ZHAN Wen, LI Xiaobin, ZHANG Shanshan, JIN Meng, HE Qiuxia. Study of the active components and mechanism of action of antithrombotic Xuefuzhuyu oral liquid based on network pharmacology and molecular docking technology [J]. Shandong Science, 2024, 37(4): 26-33.
[6]	MA Shijing, HE Chunyan, GUAN Tianzhu, YAO Xueshuang, ZHANG Junpeng. Exploration of antihyperlipidemia mechanism of Monopterus albus peptides based on hyperlipidemic zebrafish model and network pharmacology [J]. Shandong Science, 2024, 37(3): 27-38.
[7]	WEI Zekun, YANG Yujie, LIU Shuang, WANG Yan, DONG Hongjing, LIU Chunmei. Reverse mining of Chinese medicine for intervention of liver cancer based on GEO database combined with network pharmacology and molecular docking technology [J]. Shandong Science, 2024, 37(3): 39-47.
[8]	LIU Kechun, WANG Yongcheng, ZANG Xiaohan, XIA Qing, ZHANG Yun, ZHANG Shanshan, SUN Chen. Advancements in network pharmacology and zebrafish modeling for studying traditional Chinese medicine’s effective substances and mechanisms of action [J]. Shandong Science, 2024, 37(2): 29-35.
[9]	FU Zhaoju, CHENG Guo, LIN Dengmei, LI Jun, ZHANG Nannan. Experimental study and network pharmacological analysis of the anti-inflammatory action mechanism of Mahonia bealei (Fort.) Carr. [J]. Shandong Science, 2024, 37(1): 24-31.
[10]	CHEN Chun, QI Daqing, PAN Jingwen. Clinical significance of stromal cell score in gastric cancer and intervention with Weifuchun capsules [J]. Shandong Science, 2023, 36(6): 38-47.
[11]	MU Nana, LIAO Binbin, LI Zhen, LI Jipin, LI Yihua, WANG Ying, CHEN Xubing. Investigating the mechanism of action of Elephantopus scaber L. in the treatment of ulcerative colitis based on network pharmacology and molecular docking [J]. Shandong Science, 2023, 36(6): 48-55.
[12]	WANG Yifan, ZHANG Zhe, TIAN Caijun. Mechanism of Sanhuang Xiexin decoction in treatment of Alzheimer's disease based on network pharmacology and molecular docking method [J]. Shandong Science, 2023, 36(5): 19-26.
[13]	FU Mengya, AO Huihao, BU Chao, PENG Tangyi, WU Deling, HAN Yanquan, HONG Yan. Forecast analysis of the quality markers of Zingiberis Rhizoma based on fingerprints and network pharmacology [J]. Shandong Science, 2023, 36(4): 35-41.
[14]	YIN Zhipeng, GAO Yunyun, LIU Wenwen, GUO Pengbo, ZHAO Yinghui. Exploring the mechanism of Xiangsha Liujunzi Decoction in treating Helicobacter pylori-associated gastritis based on network pharmacology and molecular docking technology [J]. Shandong Science, 2023, 36(4): 52-60.
[15]	SUN Tiefeng, DONG Limin, JIAO Ziqi, WANG Ping. Exploration of the dosing pattern and anti-respiratory syncytial virus mechanism of traditional Chinese medicine based on data mining and network pharmacology [J]. Shandong Science, 2023, 36(3): 1-9.